Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

GU Cancers 2020 | Actionable genomic alterations in RCC

Kyrollis Attalla, MD, Memorial Sloan Kettering Cancer Center, New York, NY, discusses the findings of a study describing the prevalence and landscape of actionable genomic alterations in renal cell carcinoma (RCC). Leading altered genes included TSC1 mutation, PIK3CA mutation and MET amplification. This interview took place at the 2020 Genitourinary Cancers Symposium, held in San Francisco, CA.